Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

An open-label extension study with recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) for patients whose metastatic breast cancer progressed during treatment on protocol H0648g.
trastuzumab
H0659G
HER2-positive metastatic breast cancer
Phase 3
 
July 2015

Powered by ideaPoint, Inc.